Zomanex is a venture-backed drug delivery company using our patented ORAZOM technology to transform BCS (Biopharmaceutical Classification System) Class II and Class IV therapeutics. 40 Class II and 20 Class IV marketed products, generics & brand, have been identified as ORAZOM opportunities. Our lead programmes; 2 Class IV chemotherapies, Paclitaxel & Docetaxel, transformed intravenous to oral. Our goal: new product output every 24 months.